Evobrutinib

N/A

Report date: 2026/05/16 20:00:17
NME

Base Information

Drug NameEvobrutinib
Drug Alias NameM-2951MSC-2364447MSC-2364447-CMSC2364447C
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase BTK inhibitors
TargetsTyrosine-protein kinase BTK
Therapy Area/IndicationsLupus Erythematosus, SystemicRenal InsufficiencyMultiple Sclerosis, Relapsing-Remitting +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBosnia and Herzegovina +[56] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesMerck Serono
China Registration ClassN/A

Develop Information

Active CompaniesMerck Healthcare Kgaa, Darmstadt, Germany, An Affiliate Of Merck Kgaa, Darmstadt, GermanyMerck KGaA, Darmstadt, Germany
Inactive CompaniesEmd Serono Research & Development Institute Inc
Active IndicationsN/A
Inactive IndicationsLupus Erythematosus, SystemicRenal InsufficiencyMultiple Sclerosis, Relapsing-Remitting +[6] 

Other Information

ATC CodeN/A
Related LinksDrugBankKEGG